Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
Recruiting · NCT04434040 · Registry updated 2026-05-04Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA) | Neoplasm, Residual, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Residual Cancer, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 2 | 2026-05-04 | NCT04434040 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Dana-Farber Cancer Institute | 324 |
| Genentech, Inc. | 221 |
| Stand Up To Cancer | 20 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Dana-Farber Cancer Institute | Boston | United States | 626 |
| University of California San Francisco | San Francisco | United States | 27 |
| University of Chicago Comprehensive Cancer Center at Silver Cross Hospital | New Lenox | United States | 7 |
| University of Chicago Medical Center | Chicago | United States | 152 |
| University of Chicago Medical Center for Advanced Care Orland Park | Orland Park | United States | 1 |
| University of Pennsylvania-Abramson Cancer Center | Philadelphia | United States | 3 |
| Vanderbilt-Ingram Cancer Center | Nashville | United States | 48 |